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1. Introduction 
The discovery and study of the budding yeast Saccharomyces cerevisiae var. boulardii (Sb) is 
strictly related to the concept of health promoting microorganisms from food. The first most 
well-known and popularized throughout Europe assumption of health promoting food 
containing living microorganisms was yogurt. Appointed in 1888 by Louis Pasteur, Ilya 
Ilyich Metchnikov working in Paris developed a theory that aging is caused by toxic bacteria 
in the gut and that lactic acid could prolong life which resulted in popularization of yogurt 
consumption. Metchnikov received with Paul Ehrlich the Nobel Prize in Medicine in 1908 
for his previous work on phagocytosis, which probably promoted his idea of today’s so 
called functional food further and triggered subsequent research on this subject. Scientists 
started to look for traditional, regional food products considered good for health. One of 
them was French scientist Henri Boulard who was in IndoChina in 1920 during cholera 
outbreak. He observed that some people chewing the skin of lychee and mangosteen or 
preparing special tea did not develop the symptoms of cholera. This observation lead Henri 
Boulard to the isolation of a tropical strain of yeast named Saccharomyces boulardii (Sb) from 
lychee and mangosteen fruit, which is nowadays the only commercialized probiotic yeast.  
At the beginning Metchnikov's theory that lactic acid bacteria (LAB) can prolong life was 
disputable and some researchers doubted it. For example, Cheplin and Rettger (1920)[1] 
demonstrated that Metchnikov's strain, today called Lactobacillus delbrueckii subsp. bulgaricus, 
could not live in the human intestine. A scientific discussion to be constructive needs to forge 
and define new argued ideas. Such a new term was probiotic (pro Lat. “for” and biotic Greek 
adjective from bios “life”) used by Werner Kollath [2] in 1953 to denote, in contrast to harmful 
antibiotics, all good organic and inorganic complexes. It is attributed to Lilly and Stillwel [3] 
who in 1965 defined the probiotic as “a substance produced by one microorganism 
stimulating the growth of another microorganism”. The significance of probiotics evolved 
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over time. In 1974 Parker [4] defined it as “organisms and substances which contribute to 
intestinal microbial balance”, in 1989 Fuller [5] defined it as “a live microbial feed 
supplement, which beneficially affects the host animal by improving its intestinal microbial 
balance”, in 1996 Sanders [6] wrote “Probiotics, simply defined, are microbes consumed for 
health effect. The term probiotic is used in food applications. The term biotherapeutic is used 
in clinical applications”. To distinguish between the beneficial effect of living microorganism 
from organic compounds the term prebiotic was introduced for the latter. However, living 
microorganism during their growth always affect the chemical composition of the 
environment, thus it is very difficult to differentiate the influence of microorganisms alone 
from the impact of organic compounds resulting from microorganisms metabolism. 
Unfortunately, there is still no general agreement to clear-cut definition of the probiotic.  
Irrespectively of the assumed probiotic definition, during over half of the last century the 
conducted research showed that Sb may be beneficial for human health [7]. As mentioned 
before, the history of probiotic strain started in 1920. Henri Boulard after his return to France 
patented isolated strain and in 1947 sold it to Biocodex company created for its production. 
Sb was registered as a drug for the first time in 1953 and so far it is the only registered 
eukaryotic probiotic microorganism. 
While commercial application of Sb in diarrhea treatment has been steadily growing since 
1953, the scientific interest measured in number of publications was in a “lag phase” during 
next 30-40 years. While searching year by year Scholar Google for “boulardii” it has been 
found out that there were no articles after 1953, with the first appearing in 1977. From 1977 
to 1986 only 17 publications were found. 
 
Figure 1. Number of peer-reviewed publications mentioning Sb from 1976 to 2010. 
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The publication of two successive patents in 1986 “Method for preventing or treating 
pseudo-membranous colitis” [8] and in 1987 “Method for the treatment of amoebiasis” [9], 
was probably the turning point. Thus, while in 1987 there were only 7 publication in 2011 
there were already 822.  
Why has S. boulrdii been so extensively studied in recent years? Diarrheal diseases are of 
various origin and continue to represent a major threat to global health. In developing 
countries, mortality due to acute diarrhea, especially in children, is alarmingly high. In 
contrast, in developed countries, mortality caused by diarrheal diseases may be considered 
marginal, yet these disorders are burdensome and widespread, having important economic 
impact on the society. While the majority of physicians regard probiotics as a very effective 
therapy they still criticize the lack of useful clinical guidelines [10]. Indeed, beside various 
origins of diarrheal diseases there are various mechanisms of action of Sb and the fields of 
its potential application are growing.  
2. Systematic classification 
Sb is a close relative to baker’s yeast Saccharomyces cerevisiae, the most wildly used organism 
in industrial microbiology for various foodstuff products. The most obvious difference 
between them is unusually high optimal growth of Sb in the temperature (37 °C) which fits 
very well with the temperature of human body. Another important feature is better survival 
at acid pH. Yeast classification was traditionally based on their physiological and 
biochemical profiles. However, it fails to distinguish between several yeast species or 
cultivars and it resulted in a discussion whether Sb should remain as species or subspecies 
of S. cerevisiae. Thus, molecular methods have been developed and applied to yeast strain 
typing and identification. 
Table 1. summarizes some results of the investigation on differences and similarities 
between Sb and S. cerevisiae. Although S. boulardii strains differ significantly from laboratory 
strains of S. cerevisiae [11], finally according to current nomenclature like International Code 
of Botanical Nomenclature (ICBN) Sb yeasts should be referred to as S. cerevisiae var. 
boulardii [16]. It should, however, be pointed out, that strongly reduces ability to mate with 
other strains puts Sb on the evolutionary way of becoming a separate species. 
Taxonomy attempts to achieve two aims: first the classification that reflects the evolution 
and phylogenetic relationships and second the development of procedures enabling 
identification of individual species. Thus, independently of discussion on the systematic 
classification, very important issue concerns identification of species which affect human 
health. S. cerevisiae appears to be an emerging pathogen [17-19]. Thus, recent research 
concentrates on unravelling features determining the pathogenicity. It has been shown that 
yeast pathogenicity correlates with survival in oxidative stress [20] which could be triggered 
by transcription factor Rds2 [21] or activation of MAP kinases and variability in the 
polyglutamine tract of Slt2 [22]. Probiotic properties are also strain specific, which is the case 
for Sb used as probiotic [11, 12]. Thus there is a need for a valuable molecular markers able 
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to distinguish among strains and establish appropriate methods for the identification of 
probiotic strains of the Sb. Such a method could be, for example, microsatellite length 
polymorphism, having a discriminatory power of 99% [15, 23], restriction fragment length 
polymorphism [24], full genome hybridization [14], randomly amplified polymorphic DNA 
[25], GeneChip hybridization [11], artificial neural network–assisted Fourier-transform 
infrared spectroscopy [26] or multilocus enzyme electrophoresis [27]. These identification 
methods enable the discrimination between various strains but are not necessarily related to 
mechanisms of probiotic activity. Metabolic footprinting using mass spectrometry may be 
useful in this regard. Using gas chromatography–time of flight–mass spectrometry there 
was good correlation with genetic method of strains classification. Probiotic strains of Sb 
showed tight clustering both genetically and metabolically. The major discriminatory 
metabolites were: trehalose, myo-inositol, lactic acid, fumaric acid and glycerol 3-phosphate 
[28]. Next very important step is very to find out a functional relationship between specific 
DNA and probiotic action.  
 
Sb S. cerevisiae 
Higher optimal growth temperature (~37 °C) 
Lower optimal growth temperature 
(~30 °C) 
Higher resistance to low pH [11] Lower resistance to low pH [11] 
The karyotypes of Sb are very similar to those 
of S. cerevisiae 
Typing RFLPs or PCR- (ex 5.8S rDNA) 
failed to distinguish Sb from S. 
cerevisiae [12] 
Do not use galactose [13] Use galactose 
Asporogenous in contrast to S. cerevisiae but 
may produce fertile hybrids with of S. cerevisiae 
strains [11] 
Sporogenous 
Lost all intact Ty1/2 elements [14]. Contains several Ty1/2 elements 
Microsatellite typing shows genotypic 
differences [15] 
 
Trisomic for chromosome IX 
There are stable strains with various 
ploidy 
Table 1. Summary of some differences and similarities between Sb and S. cerevisiae. 
3. Medical applications of Sb  
Several published medical studies have shown the efficacy and safety of Sb for various 
disease indications both in adults and children. Regarding the medical use, different 
indications of Sb could be listed: prevention of antibiotic-associated diarrhea, recurrent 
Clostridium difficile-associated diarrhea and colitis, Travellers’ diarrhea, acute bacterial and 
viral diarrhea, diarrhea in patients with total enteral feeling, anti-inflammatory bowel 
diseases, supplement to hydration in adults and children, against diarrhea associated with 
the use of antibiotics. [29-32]. There is an increasing number of publications showing the 
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results of double blind clinical trials, clinical guidelines including new applications of the 
usage of Sb and new potential fields. While the number of different possible application of 
Sb in prevention and treatment of health disorders is growing, it is crucial to determine 
mechanisms of its action. This is an extremely difficult task due to a high number of factors 
involved in the observed health benefits. 
 
Use for disease 
Dose 
(mg/d) 
Duration Adjunct to 
Prevention of antibiotic 
associated diarrhea 
500-1000 
During antibiotics 
with additional 3 
days to 2 weeks after 
Nothing 
Prevention of Traveller’s 
diarrhea 
250-1000 
Duration of trip (3 
weeks) 
Nothing 
Enteral nutrition-related 
diarrhea 
2000 8-28 days Nothing 
H. pylori symptoms 1000 2 weeks 
Standard triple 
therapy 
Treatment of Clostridium 
difficile 
infections 
1000 4 weeks 
Vancomycin or 
metronidazole 
Acute adult diarrhea 500 - 750 8-10 days Nothing 
Inflammatory bowel 
disease 
750-1000 7 weeks to 6 months Mesalamine 
Irritable bowel syndrome 500 4 weeks Nothing 
Giardiasis 500 4 weeks Metronidazole 
HIV-related diarrhea 3000 7 days Nothing 
Table 2. Summary of recommendations for clinical use of Sb in adults [7] 
Mechanisms of action of Sb 
While Sb has been proven effective in several double-blind studies and yeast preparation is 
sold in several countries as both a preventive and therapeutic agent, not all mechanisms of 
its action have been studied [7, 33] and the new ones are still being discovered. Figure 2 
summarizes most of the postulated mechanism of Sb activity which are : 
a. antimicrobial effect, 
b. nutritional effect, 
c. inactivation of bacterial toxins,  
d. quorum sensing, 
e. trophic effects, 
f. immuno-modulatory effects 
g. anti-inflammatory effects,  
h. cell restitution and maintenance of epithelial barrier integrity. 
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Figure 2. Sb possible probiotic mechanisms of action. 
This enumeration is somehow artificial because one factor may play multiple roles and 
various processes may act synergistically.  
Antimicrobial effect may be exerted through several mechanisms. One of them is 
irreversible binding of bacteria to the yeast surface, preventing their adhesion to the mucous 
membranes and subsequent elimination by the flow Fig. 2A. It has been shown that Sb has 
the ability to bind enteric pathogens to mannose as a receptor [34]. That yeast viability was 
not necessary for the adhesion phenomenon. Furthermore it has been shown that in the 
binding beside process beside mannose-containing glycoprotein other proteins are involved 
[35]. On the other hand, Tasteyre et al. [36] showed that the yeast could inhibit adherence of 
C. difficile to cells, thanks to its proteolytic activity and steric hindrance. This is exerted 
trough the modification the eukaryotic cell surface receptors involved in adhesion of C. 
difficile. Other mechanisms exerting antimicrobial effect are utilization of substrates, 
modification of the environment and release of various compounds. 
Some of the released compounds are quorum sensing molecules Fig. 2D. They influence 
metabolism and properties of microorganisms, for example, reducing the ability to adhesion 
or filamentation, which are both important factors of strains pathogenicity [37, 38]. 
Sb may inhibit pathogens through action on microbial virulence factors. Invasive properties 
of Salmonella enterica serovar Typhimurium is closely related to the flagellum-associated 
motility. Study performed on human colonic cells infected by the S. enterica showed that in 
in presence of Sb the pathogen motility was reduced [39]. Sb also acts by inactivation of 
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bacterial toxins (Fig. 2C). For example, it has been shown that the 63-kDa protein 
phosphatase from Sb is able to dephosphorylate and partially inactivate the endotoxin (LPS) 
of Escherichia coli. Furthermore, Sb releases in vivo a 54-kDa serine protease that digests 
toxins A and B of Clostridium difficile and the BBM receptor of toxin A [40]. 
Sb also influences the growth of gut microflora and the host by its metabolism (uptake of 
substrates and release of products or multitude of cell components by dying cells). Yeast from 
Saccharomyces genus has been used in human and animal nutrition (Fig 2 B) for many 
centuries and new applications in agro-industries are being developed [41]. They are of high 
nutritional value and are used as food additive or to obtain some products such as white or 
“living” beer. Yeast cells are also a well-known source of proteins, B-complex vitamins, nucleic 
acids, vitamins and minerals, including a biologically active form of chromium known as 
glucose tolerance factor [42]. In some countries a mixture of a small amount of baker yeast 
with water and sugar was prepared as a drink for children as supplementation with B-
complex vitamins. Sb releases during its passage through gastrointestinal track at least 1500 
various compounds [43]. While vitamins are necessary exogenous organic compound which 
must be ingested, enzymes may help to transform bigger to smaller compounds which may be 
absorbed by brush border. The brush border is the structure formed by microvilli increasing 
the cellular surface area responsible for secretion, absorption, adhesion and transduction of 
signals. Within the gastrointestinal tract brush border is crucial for digestion and nutrient 
absorption. It has been shown that oral administration of probiotic strain of Sb enhanced the 
activities of the brush border ectomembrane enzymes (ex. sucrase, maltase, trehalase, lactase, 
aminopeptidase, alkaline phosphatase), carriers (sodium glucose cotransporter-1) receptors of 
immunoglobulins (the secretory component) or secretory immunoglobulin A [44-48]. Sb cells 
contain substantial amounts of polyamines (spermidine and spermine) which are known to 
affect cell maturation, enzyme expression and membrane transport, thus polyamines were 
suggested as mediators in the intestinal trophic response [45]. Trophic effect Fig 2E has been 
recently reviewed by Buts [33, 43]. It was postulated that Sb upgraded intestinal function by at 
least three mechanisms: 
- The endoluminal secretion of various compounds by yeast 
- The secretion of polyamines triggering transduction trophic signals and resulting in 
enhanced synthesis of brush border membrane proteins (enzymes and carriers). 
Clinical studies have shown that oral administration of Sb is effective in treatment of 
inflammatory bowel diseases and control of irritable bowel syndrome. There are several 
possible mechanisms of anti-inflammatory effect (Fig 2G) recently reviewed by Pothoulakis 
[49], Vandenplas [50] or Vohra [51]. The activity may be exerted through released compounds 
which modifies epithelial cell and mucosal immune system signaling pathways. One 
mechanism of anti-inflammatory effect could be exerted by producing by Sb a heat stable low 
molecular weight (<1 kDa) soluble factor [52]. The mechanism is based on blocking activation 
of nuclear factor-kappa B (NF-B) and mitogen activated protein kinase (MAPK). As a result, 
pro-inflammatory compounds such as interleukin 8 (IL-8), tumor necrosis factor alpha (TNF- 
) and interferon gamma (IFN- ) are down regulated. Sb and Sb secreted-protein(s) inhibit 
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production of pro-inflammatory cytokines by interfering with the global mediator of 
inflammation nuclear factor B, and modulating the activity of the mitogen-activated protein 
kinases ERK1/2 [53] and p38 [54]. Sb activates expression of peroxisome proliferator-activated 
receptor-gamma (PPAR-γ) that protects the digestive track from inflammation. Sb also 
suppresses ‘bacteria overgrowth’ and host cell adherence as described before. 
Another mechanism mutually related to inflammation and synergistically acting with 
antimicrobial and anti-inflammatory effect [55] is immunomodulation Fig 2F. Sb has been 
shown to increase secretion of immunoglobulin A [48]. Immunomodulation could be exerted 
by Sb interactions with mucosal dendritic cells. Dendritic cells discriminate commensal 
microorganisms from potential pathogens and take part in maintaining the balance between 
tolerance and active immunity. They respond to intestinal inflammation and thus are potential 
target in inflammatory bowel disease [56]. Dendritic cells produce regulatory cytokines and 
induce T cells. Sb inhibits dendritic cell-induced activation of naïve T cells [57] and may 
interfere with IBD pathogenesis by trapping T cells in mesenteric lymph nodes [58]. 
Bacterial infections leading to inflammatory bowel diseases results in intestinal epithelial 
cell damage. Thus, remission of these diseases requires both the cessation of inflammation 
and the cell restitution Fig. 2H within the damaged epithelium, which is effected by 
enterocyte migration. It has been recently shown that Sb accelerate enterocyte migration by 
secretion of motogenic factors that enhance cell restitution through the dynamic regulation 
of α2β1 integrin activity [59]. 
4. Effect of Sb on the virulence factors of Candida albicans 
While there is quickly increasing information on the influence of Sb on the bacterial origin 
diseases the interaction between Sb and Candida albicans is much less studied filed. C. 
albicans is a dimorphic fungus growing commensally in the gastrointestinal tract of healthy 
humans. Switching between morphotypes is a striking feature enabling the growth as 
budding yeast or as filamentous forms. It also enables in formation of complicate biofilm 
structures [60]. The transition between morphotypes contributes to the overall virulence and 
constitutes potential target for development of antifungal drugs.  
 
Figure 3. Phenotypic switching of C. albicans. (A) budding yeast, (B) pseudohyphal growth, (C) hyphal 
growth. 
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Pathogenicity of C. albicans, like all pathogens, is conditioned by their virulence. All the 
features that improve microbial colonization of host cells, multiplication and spread within 
organism or toxins production, which in turn leads to the development of the disease are 
called virulence factors. The virulence of C. albicans include: the ability to adhesion, biofilm 
formation and production of coatings, as well as morphological transformation, phenotypic 
switching and secretion of proteases, phospholipases and endotoxin [61]. Morphogenesis in 
C. albicans can be impaired by various small molecules such as farnesol, fatty acids, sugars, 
rapamycin, geldanamycin, histone deacetylase inhibitors, and cell cycle inhibitors recently 
reviewed by Shareck [62]. Affecting metabolism of the C. albicans may also have indirect 
effect as for example synergism with the antifungal drugs. Indeed metabolic state of the cell 
greatly affects activity of the PDR pump activity [63]. 
It has been shown that both live Sb cells and the extract from Sb culture filtrate diminish C. 
albicans adhesion to and subsequent biofilm formation [38]. Thus, independently of the 
trophic relationships, for example, elimination from the medium of carbon source (sugars) 
or polyunsaturated fatty acids [64], Sb releases to the medium active compounds. These 
compounds in dose dependent manners are able to inhibit switching from budding yeast to 
hyphae growth. The extract prepared from Sb culture filtrate was showed to contain 2-
phenylethanol, caproic, caprylic and capric acid. The highest activity reducing candidal 
virulence factors was capric acid (C10:0), which is responsible for inhibition of hyphae 
formation. It also reduced candidal adhesion and biofilm formation, though three times less 
than the extract. Thus Sb release to the medium other factors, not yet identified, suppressing 
C. albicans adherence [37]. Capric acid acts through the activation of cAMP pathways and 
Hog1 kinase cascade, reducing the expression of genes of C. albicans virulence. Capric acid 
reduces CSH1, INO1, HWP1 transcripts. CSH1 encodes a protein related to the 
hydrophobicity surface of the fungal cell wall and is involved in adhesion. INO1 encodes an 
enzyme involved in the biosynthesis of inositol, which is a precursor components on the 
surface of the cell wall of C. albicans involved in the virulence. HWP1 (Hyphal Wall Protein) 
encodes protein present in hyphae and pseudogyphae and involved in adhesion and biofilm 
formation. Besides inhibition of C. albicans adhesion to epithelial cell lines, Sb living cells and 
compounds released to the medium, reduced cytokine-mediated inflammatory host 
response. In fact the IL-8 gene expression was suppressed in C. albicans-infected epithelial 
cells by the compounds released to the medium by Sb [65].  
It is clear that Sb secretes many compounds and some of them may act as quorum sensing 
and modulate growth of other microorganisms including other eukaryotes such as C. 
albicans. Besides identified compounds and their activity it is clear that there are still other 
biologically active compounds produced by Sb which remain to be discovered [65]. 
5. Conclusions and future perspectives 
A century after publication of the Metchnikov's theory there is no more doubt concerning 
potential positive influence of selected strains of living microorganisms in the ingested food 
on human health. Nevertheless, the discussion has been even more turbulent and the topic 
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is “hot”, as seen from increasing number of scientific publications. In contrast to most of the 
registered drugs which are single, pure compounds, Sb has been shown to be beneficial 
through various mechanism. Thus, due to very complex and various interactions it is exiting 
research area with a lot of things to discover, but it is also extremely laborious, costly and 
time consuming. There is a number of organisms in traditional fermented food that has been 
shown to be potentially beneficial for human health. However, probiotic properties are 
strain specific and very often not well characterized. Properties of strains from the same 
species may be very different, thus for human health benefits potential probiotic strain 
should be very well characterized. It is clear that microflora of the human body is very 
complex and it is important to maintain appropriate homeostasis, which may be unbalanced 
by use of antibiotics. This can be prevented or regained by use of appropriate probiotics. 
However, due to the complexity of the possible interactions and various mechanisms of 
actions it is very difficult to register and commercialize a new probiotic. It is a great 
challenge to resolve this bottleneck in the future.  
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